Drug intelligence / Profile preview

ALA-1300

Development stage: Preclinical
Lead developer: Alar Pharmaceuticals
Modality: Small Molecules
Administration: Subcutaneous

Overview

ALA-1300 is a subcutaneous injectable depot formulation of buprenorphine being developed by Alar Pharmaceuticals. It is currently in preclinical development for the treatment of pain and opioid-related disorders. As a buprenorphine formulation, it works through opioid receptor activity, primarily as a partial agonist at the mu-opioid receptor while also acting on delta and kappa opioid receptors.

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NOP (Nociceptin/orphanin FQ peptide receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on ALA-1300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALA-1300.

Explore the full profile